New prostate cancer treatment approved by FDA
A targeted radioligand therapy, Pluvicto (lutetium LU 177 vipivotide tetraxetan), has been
approved for use in patients with previously treated metastatic castration-resistant prostate
cancer (mCRPC). Eligible patients must have been treated previously with taxane-based
chemotherapy and androgen deprivation therapy, and test positive for PSMA.
VISION, a randomized, open-label trial compared best standard of care alone vs with lutetium
LU177 vipivotide tetraxetan in 831 men with PSMA-positive mCRPC that was progressing.
Patients were randomly assigned in a 2:1 ratio to receive either the best standard of care plus
lutetium Lu 177 vipivotide tetraxetan, 7.4 GBq (200 mCi) every 6 weeks until as many as 6 doses
were given, or to the best standard of care alone.
VISION showed a statistically significant improvement in overall survival with lutetium LU 177
vipivotide tetraxetan. The Lu177 was given intravenously every 6 weeks until 6 doses were
given, the cancer progressed or there were unacceptable toxicity results.
The 2021 Summer/Fall Quest (Volume 29, Number 2) cover story, “The Room Where It
Happened…” describes the historical background of PSMA targeted PET scan imaging agents for prostate cancer and information on this new class of therapy that targets and kills prostate cancer cells in the body.